CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Helius Medical Technologies, Inc. - HSDT CFD

    7.6396
    6.6%
    0.1508
    Low: 7.5496
    High: 8.2796
    Market Trading Hours* (UTC) Opens on Tuesday at 13:30

    Mon - Fri: 13:30 - 20:00

    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.1508
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026151 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026151%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003929 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003929%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 0.02
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Helius Medical Technologies Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 8.1796
    Open* 8.1496
    1-Year Change* 2374.83%
    Day's Range* 7.5496 - 8.2796
    52 wk Range 5.69-29.50
    Average Volume (10 days) 2.19M
    Average Volume (3 months) 7.67M
    Market Cap 4.55M
    P/E Ratio -100.00K
    Shares Outstanding 565.97K
    Revenue 787.00K
    EPS -120.55
    Dividend (Yield %) N/A
    Beta 1.26
    Next Earnings Date Nov 13, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Sep 22, 2023 8.1796 -0.3000 -3.54% 8.4796 10.8996 8.1796
    Sep 21, 2023 8.5696 -0.1300 -1.49% 8.6996 8.8896 8.3996
    Sep 20, 2023 8.4496 0.2000 2.42% 8.2496 8.8396 8.2496
    Sep 19, 2023 8.4596 -0.2400 -2.76% 8.6996 8.8796 8.1596
    Sep 18, 2023 8.7196 0.4200 5.06% 8.2996 8.7596 8.2996
    Sep 15, 2023 8.2996 0.0500 0.61% 8.2496 8.4496 7.9996
    Sep 14, 2023 8.5096 0.3100 3.78% 8.1996 8.7496 8.1996
    Sep 13, 2023 8.3496 0.3500 4.38% 7.9996 8.4496 7.9996
    Sep 12, 2023 8.2696 -0.5200 -5.92% 8.7896 8.7896 8.1096
    Sep 11, 2023 8.9996 -0.8000 -8.16% 9.7996 10.3496 8.6196
    Sep 8, 2023 9.4330 1.5900 20.27% 7.8430 10.9230 7.8430
    Sep 7, 2023 7.8530 -0.1400 -1.75% 7.9930 8.6230 7.5030
    Sep 6, 2023 8.8930 -0.2800 -3.05% 9.1730 9.3630 7.5930
    Sep 5, 2023 9.8930 -2.2800 -18.73% 12.1730 12.5830 9.6030
    Sep 1, 2023 7.3630 1.0700 17.00% 6.2930 7.8730 6.2830
    Aug 31, 2023 6.7730 -0.3600 -5.05% 7.1330 8.6430 6.6730
    Aug 30, 2023 7.7230 1.2500 19.31% 6.4730 7.8930 6.2130
    Aug 29, 2023 7.1730 0.6800 10.47% 6.4930 7.2930 6.4930
    Aug 28, 2023 6.4930 0.7800 13.65% 5.7130 6.5030 5.7130
    Aug 25, 2023 5.8130 -0.2000 -3.33% 6.0130 6.4330 5.6830

    Helius Medical Technologies, Inc. Events

    Time (UTC) Country Event
    Monday, November 13, 2023

    Time (UTC)

    13:30

    Country

    US

    Event

    Q3 2023 Helius Medical Technologies Inc Earnings Release
    Q3 2023 Helius Medical Technologies Inc Earnings Release

    Forecast

    -

    Previous

    -
    Thursday, March 7, 2024

    Time (UTC)

    10:59

    Country

    US

    Event

    Q4 2023 Helius Medical Technologies Inc Earnings Release
    Q4 2023 Helius Medical Technologies Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0.787 0.522 0.661 1.496 0.478
    Total Operating Expense 16.303 18.664 15.047 25.492 27.153
    Selling/General/Admin. Expenses, Total 10.64 12.158 9.404 16.521 17.214
    Research & Development 4.262 5.99 4.582 8.061 9.939
    Operating Income -15.516 -18.142 -14.386 -23.996 -26.675
    Interest Income (Expense), Net Non-Operating 1.437 0.01 0.193 14.12 -2.011
    Other, Net 0.007 0 0.063 0.095 0.063
    Net Income Before Taxes -14.072 -18.132 -14.13 -9.781 -28.623
    Net Income After Taxes -14.072 -18.132 -14.13 -9.781 -28.623
    Net Income Before Extra. Items -14.072 -18.132 -14.13 -9.781 -28.623
    Net Income -14.072 -18.132 -14.13 -9.781 -28.623
    Income Available to Common Excl. Extra. Items -14.072 -18.132 -14.13 -9.781 -28.623
    Income Available to Common Incl. Extra. Items -14.072 -18.132 -14.13 -9.781 -28.623
    Diluted Net Income -14.072 -18.132 -14.13 -9.781 -28.623
    Diluted Weighted Average Shares 0.26994 0.04914 0.02396 0.01506 0.01302
    Diluted EPS Excluding Extraordinary Items -52.1295 -369.019 -589.844 -649.559 -2198.38
    Dividends per Share - Common Stock Primary Issue
    Diluted Normalized EPS -49.3252 -368.653 -576.904 -649.559 -2198.38
    Total Extraordinary Items
    Revenue 0.787 0.522 0.661 1.496 0.478
    Cost of Revenue, Total 0.463 0.298 0.388 0.846 0
    Gross Profit 0.324 0.224 0.273 0.65 0.478
    Depreciation / Amortization 0.181 0.2 0.363 0.064 0
    Dilution Adjustment 0
    Unusual Expense (Income) 0.757 0.018 0.31
    Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021
    Total revenue 0.282 0.196 0.119 0.19 0.258
    Revenue 0.282 0.196 0.119 0.19 0.258
    Cost of Revenue, Total 0.15 0.101 0.088 0.124 0.129
    Gross Profit 0.132 0.095 0.031 0.066 0.129
    Total Operating Expense 2.951 5.049 3.549 4.754 4.36
    Selling/General/Admin. Expenses, Total 1.967 3.393 2.461 2.819 2.376
    Research & Development 0.794 0.751 0.953 1.764 1.808
    Depreciation / Amortization 0.04 0.047 0.047 0.047 0.047
    Operating Income -2.669 -4.853 -3.43 -4.564 -4.102
    Interest Income (Expense), Net Non-Operating -2.223 3.823 -0.38 0.217 0
    Other, Net 0.006 0 0 0.001 0
    Net Income Before Taxes -4.886 -1.03 -3.81 -4.346 -4.102
    Net Income After Taxes -4.886 -1.03 -3.81 -4.346 -4.102
    Net Income Before Extra. Items -4.886 -1.03 -3.81 -4.346 -4.102
    Net Income -4.886 -1.03 -3.81 -4.346 -4.102
    Income Available to Common Excl. Extra. Items -4.886 -1.03 -3.81 -4.346 -4.102
    Income Available to Common Incl. Extra. Items -4.886 -1.03 -3.81 -4.346 -4.102
    Diluted Net Income -4.886 -1.03 -3.81 -4.346 -4.102
    Diluted Weighted Average Shares 0.56394 0.17087 0.07857 3.78787 3.13886
    Diluted EPS Excluding Extraordinary Items -8.66398 -6.02811 -48.4893 -1.14735 -1.30684
    Diluted Normalized EPS -8.66398 -1.59774 -48.4893 -1.14735 -1.30684
    Dividends per Share - Common Stock Primary Issue 0 0 0
    Unusual Expense (Income) 0 0.757
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 16.697 12.594 4.685 7.241 26.961
    Cash and Short Term Investments 14.549 11.005 3.331 5.459 25.583
    Cash 14.549 11.005 3.331 5.459 25.583
    Total Receivables, Net 0.343 0.251 0.23 0.574 0.275
    Accounts Receivable - Trade, Net 0.071 0.066 0.074 0.21 0.275
    Prepaid Expenses 1.216 0.862 0.735 0.61 0.447
    Total Assets 17.287 14.102 6.547 10.347 27.827
    Total Current Liabilities 1.988 2.653 2.424 3.802 17.973
    Payable/Accrued
    Notes Payable/Short Term Debt 0 0 0 0
    Other Current Liabilities, Total 0.027 0.148 0.281 0.435 13.769
    Total Liabilities 9.136 2.846 2.676 4.512 17.973
    Total Long Term Debt 0 0 0 0
    Total Equity 8.151 11.256 3.871 5.835 9.854
    Common Stock 0.028 0.004 0.001 0.031 0.026
    Additional Paid-In Capital 159.618 149.412 123.872 111.479 105.411
    Retained Earnings (Accumulated Deficit) -151.107 -137.035 -118.903 -104.773 -94.992
    Other Equity, Total -0.388 -1.125 -1.099 -0.902 -0.591
    Total Liabilities & Shareholders’ Equity 17.287 14.102 6.547 10.347 27.827
    Total Common Shares Outstanding 28.2073 3.78067 1.48436 0.87763 0.7379
    Property/Plant/Equipment, Total - Net 0.45 0.412 0.576 1.264 0.554
    Property/Plant/Equipment, Total - Gross 0.653 0.779 1.449 0.63
    Accumulated Depreciation, Total -0.241 -0.203 -0.185 -0.076
    Other Long Term Assets, Total 0 0.018 0.018
    Accounts Payable 0.627 1.069 0.747 1.676 2.392
    Accrued Expenses 1.334 1.436 1.396 1.691 1.812
    Total Inventory 0.589 0.476 0.389 0.598 0.392
    Other Current Assets, Total 0 0.264
    Note Receivable - Long Term 0 0.294
    Other Liabilities, Total 7.148 0.193 0.252 0.71 0
    Goodwill, Net 0 0.763 0.759 1.242
    Intangibles, Net 0.14 0.333 0.527 0.582
    Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021
    Total Current Assets 16.697 18.217 5.064 8.026 12.594
    Cash and Short Term Investments 14.549 16.658 3.273 6.31 11.005
    Cash 14.549 16.658 3.273 6.31 11.005
    Total Receivables, Net 0.343 0.217 0.196 0.245 0.251
    Accounts Receivable - Trade, Net 0.071 0.021 0.009 0.06 0.066
    Total Inventory 0.589 0.609 0.577 0.52 0.476
    Prepaid Expenses 1.216 0.733 0.996 0.951 0.862
    Total Assets 17.287 18.859 6.546 9.618 14.102
    Property/Plant/Equipment, Total - Net 0.45 0.464 0.493 0.52 0.412
    Goodwill, Net 0 0.753 0.777 0.763
    Intangibles, Net 0.14 0.178 0.236 0.291 0.333
    Other Long Term Assets, Total 0.004
    Total Current Liabilities 1.988 1.2 1.777 2.199 2.653
    Accounts Payable 0.627 0.57 1.043 1.111 1.069
    Accrued Expenses 1.334 0.604 0.706 1.059 1.436
    Other Current Liabilities, Total 0.027 0.026 0.028 0.029 0.148
    Total Liabilities 9.136 5.898 2.044 2.488 2.846
    Other Liabilities, Total 7.148 4.698 0.267 0.289 0.193
    Total Equity 8.151 12.961 4.502 7.13 11.256
    Preferred Stock - Non Redeemable, Net
    Common Stock 0.028 0.028 0.004 0.004 0.004
    Additional Paid-In Capital 159.618 159.386 150.665 149.834 149.412
    Retained Earnings (Accumulated Deficit) -151.107 -146.221 -145.191 -141.381 -137.035
    Other Equity, Total -0.388 -0.232 -0.976 -1.327 -1.125
    Total Liabilities & Shareholders’ Equity 17.287 18.859 6.546 9.618 14.102
    Total Common Shares Outstanding 28.2073 28.2013 4.19511 3.7948 3.78067
    Property/Plant/Equipment, Total - Gross 0.786 0.653
    Accumulated Depreciation, Total -0.266 -0.241
    Notes Payable/Short Term Debt 0 0 0 0
    Total Long Term Debt 0 0 0 0
    Other Current Assets, Total 0.022
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -18.132 -14.13 -9.781 -28.623
    Cash From Operating Activities -13.388 -11.738 -20.999 -19.621
    Non-Cash Items 4.305 2.926 -9.132 9.961
    Changes in Working Capital 0.127 -1.016 -2.277 -1.018
    Cash From Investing Activities -0.056 -0.009 -0.769 -0.44
    Other Investing Cash Flow Items, Total 0 0.061 -0.416
    Cash From Financing Activities 21.126 9.638 1.653 40.028
    Financing Cash Flow Items -2.889 -1.015 -0.247 -3.161
    Issuance (Retirement) of Stock, Net 24.015 10.653 1.9 43.189
    Foreign Exchange Effects -0.008 -0.019 -0.009 0.054
    Net Change in Cash 7.674 -2.128 -20.124 20.021
    Cash From Operating Activities 0.112 0.119 0.127 0.059
    Cash Taxes Paid 0 0
    Cash Interest Paid 0 0
    Capital Expenditures -0.056 -0.07 -0.353 -0.44
    Amortization 0.2 0.363 0.064
    Issuance (Retirement) of Debt, Net 0 0
    Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021
    Net income/Starting Line -9.186 -8.156 -4.346 -18.132
    Cash From Operating Activities -12.167 -8.346 -4.682 -13.388
    Cash From Operating Activities 0.074 0.05 0.025 0.112
    Amortization 0.141 0.094 0.047 0.2
    Non-Cash Items -1.768 0.765 0.195 4.305
    Changes in Working Capital -1.428 -1.099 -0.603 0.127
    Cash From Investing Activities -0.013 -0.006 0.004 -0.056
    Capital Expenditures -0.019 -0.012 -0.002 -0.056
    Cash From Financing Activities 17.869 0.62 -0.017 21.126
    Financing Cash Flow Items -0.775 -0.024 -0.017 -2.889
    Issuance (Retirement) of Stock, Net 18.644 0.644 0 24.015
    Foreign Exchange Effects -0.006 -0.008
    Net Change in Cash 5.683 -7.732 -4.695 7.674
    Other Investing Cash Flow Items, Total 0.006 0.006 0.006 0
    Issuance (Retirement) of Debt, Net 0
    Cash Interest Paid 0.927

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Helius Medical Technologies, Inc. Company profile

    About Helius Medical Technologies Inc

    Helius Medical Technologies, Inc. is a neurotech company focused on neurological wellness. The Company focuses on developing, licensing or acquiring non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The Company's product, Portable Neuromodulation Stimulator (PoNS) is a class II, non-implantable medical device intended for use as a short-term treatment (14 weeks) of gait deficit due to symptoms from multiple sclerosis (MS), and balance deficit due to mild-to-moderate traumatic brain injury (mmTBI) and is to be used in conjunction with supervised therapeutic exercise (PoNS Treatment). The Company's subsidiaries include Helius Medical, Inc., Helius Medical Technologies (Canada), Inc., Helius NeuroRehab, Inc., Helius Canada Acquisition Ltd. and Heuro Canada, Inc.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Helius Medical Technologies Inc revenues decreased 21% to $522K. Net loss increased 28% to $18.1M. Revenues reflect Product sales decrease of 21% to $493K, Fee revenue decrease from $9K to $0K. Higher net loss reflects General and administrative increase of 25% to $12.2M (expense), Research and development increase of 31% to $6M (expense), Foreign exchange gain decrease of 95% to $10K (income).

    Industry: Advanced Medical Equipment & Technology (NEC)

    642 Newtown Yardley Road
    NEWTOWN
    PENNSYLVANIA 18940
    US

    Income Statement

    • Annual
    • Quarterly

    News

    EUR/USD tests key support

    EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

    14:32, 21 September 2023
    Bank of England building

    BoE leaves rates unchanged, GBP drops further as investors look for more clarity

    The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

    11:45, 21 September 2023
    British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

    GBP softer after CPI surprise, JPY focused on any further hints from Ueda

    GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

    12:42, 20 September 2023

    How to Trade The Break & Retest

    In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

    11:59, 20 September 2023

    Cable coils near lows ahead of Fed and BoE rate decisions

    It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

    14:16, 19 September 2023

    FTSE 100 Technical Outlook - 18 September 2023

    In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

    06:55, 19 September 2023
    View of the City of London’s illuminated financial district skyline at dusk

    Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally

    The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.

    13:46, 15 September 2023

    People also watch

    US100

    14,695.60 Price
    -0.060% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0039%
    Overnight fee time 21:00 (UTC)
    Spread 1.8

    XRP/USD

    0.51 Price
    +0.070% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01192

    BTC/USD

    26,393.15 Price
    -0.520% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 85.00

    ETH/USD

    1,594.92 Price
    +0.210% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 5.40

    Still looking for a broker you can trust?

    Join the 555.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading